StockData
Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc. (TRDA) stock

TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$5.03+0.07 (+1.41%)

Close on Nov 18, 2026Market cap $195.85MP/E –Yield –

Entrada Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Entrada Therapeutics

Entrada Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Entrada Therapeutics figures

See a number that looks wrong?